Cellectric is developing a direct-from-blood application for sepsis samples that selectively destroys human cells in the sample to avoid the need for bacteria culturing.

In total, three studies were published in Nature Medicine that together describe methods to provide more precise diagnoses of sepsis and acute illnesses ...

The company has developed a multiplex panel for bacterial and yeasts infections that it plans to submit for FDA clearance in 2027.

Last week, readers were most interested in a story about the FDA rescinding a rule issued more than a year ago covering the oversight of laboratory-developed tests.

The test is a bead-based multiplexed immunoassay that also utilizes a machine-learning classifier to determine whether a ...

Industry representatives have voiced their support for the Biotech Act, hoping it will improve financing and institutional support of IVD makers.

The company recently published a study showing that elemental patterns in single strands of hair are different in patients ...

Stakeholders noted that challenges like supply chain breakdowns and staffing shortages are too global in scope for any one ...

The company's SwiftX Virus extraction kit is used to prepare viral RNA and bacterial DNA for PCR-based testing for six arboviruses and one bacterial target.

The fully automated PCR-based testing system will be used in microbiology and virology labs to aid the detection of viral and bacterial causes of infectious diseases.

The test uses autofluorescent single-walled carbon nanotubes to detect bacterial cell death in antimicrobial-containing microfluidic channels.

The company plans to launch in 2026 a program that will provide labs with scanners free of charge in exchange for volume-based payments for biomarker tests.